Selank

The sequence extends the short tuftsin fragment with Pro–Gly–Pro. The identity and exact peptide form should be checked against the test article described in each publication; a name alone does not verify the composition or analytical quality of any material.

This file is an editorial guide to selected research records. It distinguishes biochemical identity from proposed mechanisms and from outcomes reported in particular experimental models.

• Reported identity: synthetic tuftsin-derived heptapeptide
• Reported sequence: Thr–Lys–Pro–Arg–Pro–Gly–Pro
• Verify the source paper's exact test article and methods

A 2001 study reported inhibition of plasma enkephalin-degrading activity in its assay. Separate papers examine GABA-related binding and neurotransmission-gene expression. Those are distinct lines of investigation; together they do not establish a single complete signaling chain or a definitive receptor-binding mechanism.

When reading each mechanism claim, distinguish the measured assay from the authors' interpretation. Check the experimental preparation, controls, assay conditions, measured signal, and whether the cited work directly tests the proposed target interaction.

• Peptidase inhibition is reported in a particular plasma assay
• GABA-related binding findings are assay-specific
• Do not infer a validated receptor or complete downstream pathway

Volkova and colleagues examined expression of 84 neurotransmission-related genes in rat frontal-cortex samples at two post-administration time points using real-time PCR. The paper reports expression changes and discusses GABAergic modulation as one possible mechanism. Gene-expression observations are not direct proof of receptor binding or of a complete functional pathway.

The 2001 peptidase paper addresses a different question using plasma enzyme activity. Keep the study material, experimental model, assay, controls, endpoints, and interpretation attached to each citation rather than merging them into one claim.

• 2016: rat frontal-cortex gene-expression analysis using real-time PCR
• 2001: plasma enkephalin-degrading enzyme assay
• Different assays should not be treated as interchangeable evidence

The 2017 study examined Selank and diazepam in a rat unpredictable chronic mild-stress model using an elevated-plus-maze behavioral endpoint. It is a preclinical design with specific groups and conditions; it is not a direct comparison with the biochemical enzyme assay or the rat gene-expression experiment.

A separate 2008 indexed study record describes a clinical investigation. Read that record and its full paper independently, with attention to design, population, comparator, measurement, and reporting limits. Do not collapse studies of different types into a single level of evidence or treat a comparison as proof of a shared mechanism.

• 2017: rat stress-model study with a behavioral assay
• 2016: gene-expression study with molecular endpoints
• 2001: biochemical plasma enzyme assay
• Separate-study context is not a head-to-head mechanistic test

The cited literature includes biochemical, molecular, preclinical behavioral, and clinical-record sources. These records differ in design and evidentiary scope. Gene-expression shifts do not by themselves demonstrate a receptor interaction; an enzyme assay does not establish a complete signaling pathway; and findings from one model should not be generalized beyond its methods.

A stronger evidence map would assess independent replication, exact test-article characterization, assay validation, and whether proposed target interactions were directly tested. Unresolved points belong in the record as open questions, not conclusions inferred from adjacent research.

• A reported sequence does not establish batch-specific identity or quality
• Mechanistic proposals remain distinct from directly measured observations
• Study model, assay, comparator, and replication constrain interpretation
• Further independent evidence is needed to resolve the full mechanism